GLP-1 Weight-Loss Drugs Outpace Europe’s Health Systems, Obesity Experts Warn

Obesity medicines have never been more effective, and Europe has never been less prepared to deliver them. That is the central warning of a new position statement from the European Association for the Study of Obesity (EASO), published in The Lancet Regional Health – Europe, which argues that the continent’s health systems risk squandering the most powerful weight-loss therapies ever developed unless they undergo structural reform. The statement, authored by a multidisciplinary team of obesity specialists, epidemiologists, and policy experts, describes what it calls the EASO Integration Paradox: therapeutic innovation in incretin-based drugs has raced far ahead of the workforce, monitoring systems, reimbursement frameworks, and care infrastructure needed to translate clinical trial results into sustainable population health.

The scale of the underlying problem is stark. Prevalence of obesity has more than doubled among European adults since 1990, and nearly sixty percent of adults in the WHO European Region now live with overweight or obesity, with children and adolescents following similar trajectories. Obesity is increasingly understood as a chronic, relapsing, adiposity-based disease with consequences that extend well beyond weight itself, including type 2 diabetes, cardiovascular disease, chronic kidney disease, metabolic dysfunction-associated steatotic liver disease, several cancers, and degraded quality of life. Against this backdrop, drugs such as semaglutide and tirzepatide, which mimic the gut-derived incretin hormones that regulate appetite and metabolism, have achieved weight reductions that were once attainable only through bariatric surgery, while simultaneously improving cardiometabolic risk factors.

The evidence base for these therapies continues to broaden in ways that are pulling new medical specialties into obesity care. Large outcome trials have demonstrated cardiovascular benefits, and meta-analyses of randomized trials point to protective effects on kidney outcomes, while recent guidance in hepatology now incorporates semaglutide therapy for metabolic dysfunction-associated steatohepatitis. A World Health Organization guideline on GLP-1-based therapies and an updated EASO framework for pharmacological treatment reflect this shift. Yet the EASO authors stress that both documents converge on the same principle: pharmacotherapy must be embedded within comprehensive obesity care rather than prescribed as a standalone fix. The problem, they argue, is that the machinery of European healthcare is not built to honor that principle at scale.

Part of the difficulty is biological. Obesity is a chronic disease, and the maintenance studies tell a sobering story: continued pharmacotherapy sustains weight loss and cardiometabolic improvements, but discontinuation is frequently followed by weight regain. Trial extensions after semaglutide withdrawal, along with maintenance trials of tirzepatide, indicate that these medicines behave like long-term chronic disease treatments, not short courses of therapy. The statement also notes that recent maintenance trials highlight open questions about individualized long-term strategies, dose optimization, and dose tapering. This chronicity multiplies the demands on health systems, which must now plan for years or decades of monitoring, adherence support, and pharmacovigilance rather than discrete treatment episodes.

To meet this challenge, the EASO authors propose an Integration Framework organized around five interdependent pillars: Right Patient, Right Care, Right Workforce, Right Data, and Right Access. The first pillar, Right Patient, calls for selection and prioritization based on transparent, evidence-informed criteria that weigh obesity severity, complications, clinical phenotype, treatment history, and patient preferences rather than body mass index alone. It further emphasizes life-course adaptation, since treatment goals and risk-benefit calculations differ between children and adolescents, reproductive life stages, and older adulthood. Age- and life-stage-specific pathways, the authors argue, should replace uniform prescribing models, with particular attention to populations underrepresented in clinical trials.

The Right Care pillar insists that incretin-based therapies be woven into multidisciplinary pathways combining nutritional support, physical activity promotion, behavioral interventions, and management of obesity-related complications. Central to this is therapeutic patient education, which the WHO Regional Office for Europe has promoted as a structured approach to supporting realistic expectations, shared decision-making, adverse-effect management, adherence, and long-term self-management. EASO’s existing network of Collaborating Centres for Obesity Management is positioned as ready-made infrastructure for piloting, evaluating, and disseminating integrated models of care across diverse healthcare settings, and potentially for generating the real-world evidence needed to determine which delivery models work best at scale.

The workforce pillar confronts an uncomfortable gap: obesity education remains limited across undergraduate, postgraduate, and continuing professional development programs in many European countries, even as prescribing expands into cardiology, nephrology, hepatology, and primary care. The statement calls for a common European obesity competency framework spanning pathophysiology, pharmacotherapy, shared decision-making, behavioral support, communication, adverse-event management, and weight-stigma reduction, built on EASO’s educational initiatives and an emerging Obesity Care Certification program. Crucially, workforce development should extend beyond physicians to the full range of health and community professionals involved in obesity management, including trained patient experts who can contribute lived experience to multidisciplinary teams.

The final two pillars address measurement and equity. Right Data calls for harmonized monitoring standards, core outcome sets, registries, and coordinated pharmacovigilance covering not just weight but central adiposity, body composition, cardiometabolic risk factors, adverse events, discontinuation reasons, and patient-reported outcomes. Safety surveillance priorities named in the statement include gastrointestinal tolerability, gallbladder disease, bone health, changes in lean mass, perioperative management, pregnancy-related exposure, and mental health outcomes. The authors see the European Health Data Space as a transformative opportunity, enabling interoperability between registries and research networks for large-scale real-world evidence generation. Right Access tackles the glaring disparities in reimbursement, eligibility criteria, waiting times, and affordability across Europe, warning that without deliberate equity-oriented design, these therapies could widen rather than narrow health inequalities. Patients and the public, the authors insist, must be actively involved in designing prioritization frameworks and access policies.

Beyond the framework itself, the statement lays out a European research and implementation agenda. It calls for pragmatic trials and registry-based studies comparing pharmacotherapy-only approaches with integrated multidisciplinary pathways, evaluated on outcomes that include physical function, treatment persistence, quality of life, and healthcare utilization, not weight loss alone. It urges development of a European minimum dataset for obesity pharmacotherapy, structured safety monitoring in long-term registries with attention to children, older adults, people with multiple comorbidities, and ethnically diverse populations, and evaluation of competency-based training programs and shared-care models. Health-economic research on reimbursement models and budget impact is flagged as increasingly decisive given the sheer number of potentially eligible individuals. Collaboration across healthcare systems, professional societies, patient organizations, and research networks, the authors conclude, will be essential. The closing message is blunt and likely to resonate far beyond the obesity field: the challenge facing Europe is no longer whether incretin-based therapies should be used, but how they should be implemented, because the future of obesity care will be determined not only by the medicines developed but by the systems built to deliver them.

Subject of Research: Integration of incretin-based pharmacotherapies into comprehensive, equitable obesity care across European health systems

Article Title: Integrating incretin-based therapies into comprehensive obesity care: an EASO position statement

Article References: Correia, J. C., Baker, J. L., Boyland, E., Busetto, L., Fábryová, L., Helgason, T., Sbraccia, P., Woodward, E., Yumuk, V., & Pataky, Z. (2026). Integrating incretin-based therapies into comprehensive obesity care: an EASO position statement. The Lancet Regional Health – Europe, 70, Article 101840. https://doi.org/10.1016/j.lanepe.2026.101840

Image Credits: AI Generated

DOI: 10.1016/j.lanepe.2026.101840

Keywords: obesity, incretin-based therapies, GLP-1 receptor agonists, semaglutide, tirzepatide, EASO, health systems, pharmacovigilance, health equity, multidisciplinary care, therapeutic patient education, European Health Data Space